Akebia Therapeutics, Inc.
2.1000-0.99 (-32%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · AKBA · USD
Key Stats
Market Cap
556.80MP/E (TTM)
-Basic EPS (TTM)
-0.18Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Akebia Therapeutics posted solid Q2 FY2025 results, with total revenue jumping 43% year-over-year to $62.5M, driven by Vafseo's U.S. launch in January 2025 contributing $13.3M in initial sales while Auryxia held steady at $47.2M despite losing exclusivity in March. Gross margin improved sharply to 84.1% from 61.0% as amortization of Auryxia intangibles wrapped up, fueling operating income of $14.1M versus a $8.7M loss last year; diluted EPS swung to breakeven from -$0.04, reconciling neatly with 271M shares. Key drivers included Vafseo uptake at mid-sized dialysis organizations and steady Auryxia volumes, though R&D rose 44% to $11.0M on clinical work for label expansion. Liquidity strengthened to $137.3M in cash, backed by $47.1M net debt under the BlackRock facility (maturing 2028 at 11.1% rate) and $40.6M Working Capital Fund liability, with no revolver draw. Yet competition from generics and rivals like roxadustat could pressure market share.
8-K
Vafseo revenues climb to $13.3M
Akebia Therapeutics reported Q2 2025 net product revenues of $60.5 million, up from $41.2 million last year, fueled by Vafseo's $13.3 million launch sales that surged 55% in prescriptions from Q1. DaVita kicks off a pilot across 100+ clinics this month, while USRC wrapped enrollment in the VOICE trial eyeing non-inferiority to ESAs. Cash hit $137.3 million, backing label expansions. Momentum builds, yet generic threats loom for Auryxia.
8-K
Stock plan shares increased
Akebia Therapeutics' stockholders approved an amendment to the 2023 Stock Incentive Plan at the June 10, 2025 annual meeting, boosting available shares by 18,900,000 to 28,900,000 total while adding a one-year vesting minimum for most awards. This bolsters talent retention amid biotech pressures. Directors John P. Butler and Myles Wolf were reelected. Dilution risk lingers for shareholders.
8-K
Vafseo launch hits $12M revenue
Akebia Therapeutics kicked off its Vafseo launch with $12.0 million in net product revenues for Q1 2025, boosting total net product sales to $55.8 million and swinging to a $6.1 million net income from last year's loss. A $50 million public offering in March lifted cash to $113.4 million, funding label expansion trials like VALOR in H2 2025. Vafseo's early traction among mid-sized dialysis providers signals strong adoption potential. Yet generic threats loom for Auryxia post-exclusivity loss.
IPO
Website
Employees
Sector
Industry
ACAD
ACADIA Pharmaceuticals Inc.
22.53-0.09
AKRO
Akero Therapeutics, Inc.
54.00+0.00
ATXI
Avenue Therapeutics, Inc.
0.72+0.00
ATXS
Astria Therapeutics, Inc.
12.60+0.13
CYCN
Cyclerion Therapeutics, Inc.
1.97-0.11
FGEN
FibroGen, Inc
10.91+0.10
KROS
Keros Therapeutics, Inc.
15.04-0.14
TAK
Takeda Pharmaceutical Company L
13.77-0.33
TLPH
Talphera, Inc.
1.23-0.07
VRTX
Vertex Pharmaceuticals Incorpor
417.21-5.18